Literature DB >> 17604134

Central but not peripheral beta-adrenergic antagonism blocks reconsolidation for a morphine place preference.

M J F Robinson1, K B J Franklin.   

Abstract

Blocking the process of memory reconsolidation by means of amnestic agents may prove to have therapeutic applications. Here we used a morphine-induced conditioned place preference as an index of drug seeking. After inducing in rats a preference for a distinctive compartment paired with morphine, the memory for drug experience was reactivated by a 20-min test session and saline, the beta-antagonist propranolol, or the peripherally acting beta-antagonist nadolol were administered. Animals which received saline or nadolol upon reactivation, or propanolol without memory reactivation, maintained their preference for the drug-paired compartment 24h and seven days later. However, animals that received propranolol upon reactivation no longer displayed a morphine preference on either test, although these animals once again expressed a preference when given a morphine-primed retest at 10 days. Our results suggest that beta-blockers may have potential for attenuating the impact of cue-induced craving which is a major cause of relapse in detoxified addicts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17604134     DOI: 10.1016/j.bbr.2007.05.023

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  32 in total

1.  Post-retrieval propranolol treatment does not modulate reconsolidation or extinction of ethanol-induced conditioned place preference.

Authors:  Laura Font; Christopher L Cunningham
Journal:  Pharmacol Biochem Behav       Date:  2012-01-21       Impact factor: 3.533

2.  β-Arrestin-biased signaling mediates memory reconsolidation.

Authors:  Xing Liu; Li Ma; Hao Hong Li; Bing Huang; You Xing Li; Ye Zheng Tao; Lan Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

3.  The NMDA antagonist MK-801 disrupts reconsolidation of a cocaine-associated memory for conditioned place preference but not for self-administration in rats.

Authors:  Travis E Brown; Brian R Lee; Barbara A Sorg
Journal:  Learn Mem       Date:  2008-12-02       Impact factor: 2.460

4.  Post-retrieval beta-adrenergic receptor blockade: effects on extinction and reconsolidation of cocaine-cue memories.

Authors:  Ashley N Fricks-Gleason; John F Marshall
Journal:  Learn Mem       Date:  2008-08-26       Impact factor: 2.460

5.  Post-retrieval disruption of a cocaine conditioned place preference by systemic and intrabasolateral amygdala beta2- and alpha1-adrenergic antagonists.

Authors:  Rick E Bernardi; Andrey E Ryabinin; S Paul Berger; K Matthew Lattal
Journal:  Learn Mem       Date:  2009-11-25       Impact factor: 2.460

6.  Inhibition of β-adrenergic receptors induces a persistent deficit in retrieval of a cocaine-associated memory providing protection against reinstatement.

Authors:  James M Otis; Devin Mueller
Journal:  Neuropsychopharmacology       Date:  2011-05-04       Impact factor: 7.853

7.  Antagonism at NMDA receptors, but not β-adrenergic receptors, disrupts the reconsolidation of pavlovian conditioned approach and instrumental transfer for ethanol-associated conditioned stimuli.

Authors:  Amy L Milton; Moritz J W Schramm; James R Wawrzynski; Felicity Gore; Faye Oikonomou-Mpegeti; Nancy Q Wang; Daniel Samuel; Daina Economidou; Barry J Everitt
Journal:  Psychopharmacology (Berl)       Date:  2011-07-16       Impact factor: 4.530

Review 8.  Stress modulation of reconsolidation.

Authors:  Irit Akirav; Mouna Maroun
Journal:  Psychopharmacology (Berl)       Date:  2012-10-06       Impact factor: 4.530

Review 9.  Translational Approaches Targeting Reconsolidation.

Authors:  Marijn C W Kroes; Daniela Schiller; Joseph E LeDoux; Elizabeth A Phelps
Journal:  Curr Top Behav Neurosci       Date:  2016

Review 10.  Noradrenergic regulation of fear and drug-associated memory reconsolidation.

Authors:  James M Otis; Craig T Werner; Devin Mueller
Journal:  Neuropsychopharmacology       Date:  2014-09-12       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.